Table 1.
Characteristic | No. of Patients(N = 1,574) | % |
---|---|---|
Demographic characteristics | ||
Age at diagnosis, years | ||
21-54 | 205 | 13 |
55-64 | 389 | 25 |
65-74 | 539 | 34 |
75+ | 441 | 28 |
Sex | ||
Male | 1,022 | 65 |
Female | 552 | 35 |
Marital status | ||
Married/living as married | 933 | 59 |
Not married | 623 | 40 |
Unknown | 18 | 1 |
Race | ||
White | 1,122 | 71 |
Hispanic/Latino | 74 | 5 |
African American | 222 | 14 |
Asian/Pacific Islander | 78 | 5 |
Other | 72 | 5 |
Unknown | 6 | 0.4 |
Insurance | ||
Medicare | 263 | 17 |
Medicaid | 158 | 10 |
Medicare plus private | 539 | 34 |
Private | 387 | 25 |
Other | 212 | 13 |
Unknown | 15 | 1 |
Clinical characteristics | ||
Comorbidity score* | ||
None | 326 | 21 |
Mild | 581 | 37 |
Moderate | 335 | 21 |
Severe | 332 | 21 |
Chemotherapy after metastasis | ||
No | 770 | 49 |
Yes | 804 | 51 |
Primary lung cancer–directed surgery after metastasis | ||
No | 1,474 | 94 |
Yes | 100 | 6 |
Metastatic site surgery† | ||
No | 1,480 | 94 |
Yes | 94 | 6 |
Provider characteristics | ||
Integrated network | ||
No | 919 | 58 |
Yes | 655 | 42 |
PDCR site | ||
Cancer Research Network | 218 | 14 |
Northern California | 322 | 20 |
Alabama | 192 | 12 |
Los Angeles | 235 | 15 |
Iowa | 336 | 21 |
Veterans Administration | 271 | 17 |
Abbreviation: NSCLC, non–small-cell lung cancer; PDCR, Primary Data Collection and Research.
Defined by using the Adult Comorbidity Evaluation 27, a validated medical record-based system that assigns each patient a four-category comorbidity score (none, mild, moderate, or severe) based on severity noted across multiple body systems, from 3 months prior to diagnosis to initial treatment.
Includes surgery to brain, bone, liver, or adrenal glands.